In an analysis of long-term safety events in 783 patients treated with T cell therapy in 38 trials, 2.3% of patients developed second primary malignancies, and vector integration analyses revealed no pathological insertions.
- Julie K. Jadlowsky
- Elizabeth O. Hexner
- Joseph A. Fraietta
